Chu, Nan-nan
Huang, Kai
Que, Lin-Ling
Ding, Ying
Gu, Xiang-hong
Zhang, Lin
Wang, Jia-kun
Chen, Xiao-ping
Sun, Zhan-guo
He, Qing
Article History
Accepted: 17 March 2022
First Online: 16 April 2022
Declarations
:
: This study was sponsored and funded by Beijing Shuobai Pharmaceutical Technology Co., Ltd.
: All authors declare no financial support from any organization for the submitted work, no commercial or financial involvements that might present a conflict of interest related to the contribution, and no other activities that influenced the submitted work.
: Basic information about the study is available at: ExternalRef removed
: Not applicable.
: Qing He and Nannan Chu designed the study. Nannan Chu wrote the manuscript and conducted the study with Kai Huang, Lin-Ling Que, Ying Ding, Xianghong Gu, Lin Zhang, and Jiakun Wang. Qing He, Xiao-Ping Chen, and Zhanguo Sun reviewed and gave valuable comments on the manuscript.
: The study was reviewed and approved by the independent ethics committee of Wuxi People’s Hospital Affiliated with Nanjing Medical University, with the approval number 2020LLPJ-I-70. The study was conducted following International Conference on Harmonization Good Clinical Practice guidelines and applicable regulations governing clinical study conduct, and ethical principles that have their origin in the Declaration of Helsinki.
: Written informed consent was obtained from all individual participants included in the study.
: Not applicable.